Table 2.
Patients’ characteristics.
| Variable | Blood No. (%) |
Respiratory No. (%) |
Skin and Soft Tissue No. (%) |
Urine No. (%) |
Others No. (%) |
|---|---|---|---|---|---|
| Total (n = 320) | 22 (7%) | 142 (44%) | 105 (33%) | 42 (13%) | 9 (3%) |
| Male Gender (n = 180) | 15 (68%) | 92 (65%) | 59 (56%) | 8 (19%) | 6 (67%) |
| Admission to Critical Care (n = 92) | 9 (41%) | 59 (42%) | 18 (17%) | 3 (7%) | 3 (33%) |
| Resistance (MDR) (n = 260) | 18 (82%) | 120 (85%) | 84 (80%) | 30 (71%) | 8 (89%) |
| Hospital Acquired (n = 190) | 15 (68%) | 92 (65%) | 55 (52%) | 23 (55%) | 5 (56%) |
| 90-day recurrence (n = 8) | 1 (5%) | 3 (2%) | 4 (4%) | 0 (0%) | 0 (0%) |
| Adverse Event (n = 147) | 9 (41%) | 93 (65%) | 37 (35%) | 7 (17%) | 1 (11%) |
| Combined Therapy (n = 175) | 14 (64%) | 92 (65%) | 49 (47%) | 13 (31%) | 7 (78%) |
| Pip/Taz Monotherapy (n = 35) | 4 (18%) | 16 (11%) | 12 (11%) | 3 (7%) | 0 (0%) |
| Pip/Taz Combined Therapy (n = 54) | 4 (18%) | 29 (20%) | 16 (15%) | 2 (5%) | 3 (33%) |
| Pip/Taz based (n = 89) | 8 (36%) | 45 (32%) | 28 (27%) | 5 (12%) | 3 (33%) |
| CST Monotherapy (n = 37) | 1 (5%) | 11 (8%) | 18 (17%) | 7 (17%) | 0 (0%) |
| CST Combined Therapy (n = 125) | 8 (36%) | 70 (49%) | 35 (33%) | 8 (19%) | 4 (44%) |
| CST based (n = 162) | 9 (41%) | 81 (57%) | 53 (50%) | 15 (36%) | 4 (44%) |
| CAZ Monotherapy (n = 31) | 1 (5%) | 11 (8%) | 9 (9%) | 9 (21%) | 1 (11%) |
| MEM Monotherapy (n = 15) | 0 (0%) | 4 (3%) | 6 (6%) | 4 (10%) | 1 (11%) |
| MEM Combined Therapy (n = 85) | 8 (36%) | 46 (32%) | 22 (21%) | 6 (14%) | 3 (33%) |
| MEM based (n = 100) | 8 (36%) | 50 (35%) | 28 (27%) | 10 (24%) | 4 (44%) |
| Other Monotherapies (n = 27) | 2 (9%) | 8 (6%) | 11 (10%) | 6 (14%) | 0 (0%) |
| TGC based Therapy (n = 37) | 4 (18%) | 25 (18%) | 6 (6%) | 0 (0%) | 2 (22%) |
| CST + MEM based (n = 59) | 4 (18%) | 36 (25%) | 15 (14%) | 3 (7%) | 1 (11%) |
| Polymicrobial Infections (n = 239) | 17 (77%) | 115 (81%) | 79 (75%) | 21 (50%) | 7 (78%) |
| ≥ 3 comorbidities (n = 127) | 8 (36%) | 58 (41%) | 49 (47%) | 9 (21%) | 3 (33%) |
MDR: Multiple Drug Resistence; Pip/Taz: Piperacillin/Tazobactam; CST: Colistin; CAZ: Ceftazidime; MEM: Meropenem; TGC: Tigecycline.